Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ...
Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Detailed price information for Alterity Therapeutics Ltd (PRNAF) from The Globe and Mail including charting and trades.
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...
MedPage Today on MSN
Is pure autonomic failure a warning sign for Parkinson's? What a new study shows.
High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...
MedPage Today on MSN
Brain Changes Tied to Single Psilocybin Dose; 50 Days to See Neurology; APOE4 and MS
News and commentary from the world of neurology and neuroscience ...
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results